Les facteurs incluent le sexe féminin, des antécédents familiaux et d'autres maladies auto-immunes.
Facteurs de risqueMaladies auto-immunesLupus érythémateux
#2
L'âge influence-t-il le risque ?
Oui, le risque est plus élevé chez les jeunes femmes, généralement entre 15 et 45 ans.
ÂgeRisqueLupus érythémateux
#3
Les antécédents médicaux jouent-ils un rôle ?
Oui, des antécédents de maladies auto-immunes augmentent le risque d'inhibiteur lupique.
Antécédents médicauxMaladies auto-immunesRisque
#4
Le stress peut-il être un facteur de risque ?
Oui, le stress peut exacerber les symptômes et augmenter le risque de complications.
StressRisqueComplications
#5
Y a-t-il des facteurs environnementaux ?
Oui, l'exposition à certains médicaments ou à des agents environnementaux peut être un facteur.
EnvironnementMédicamentsFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteur lupique de la coagulation : Questions médicales les plus fréquentes",
"headline": "Inhibiteur lupique de la coagulation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteur lupique de la coagulation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-16",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteur lupique de la coagulation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"url": "https://questionsmedicales.fr/mesh/D019774",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"code": {
"@type": "MedicalCode",
"code": "D019774",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.113"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteur lupique de la coagulation",
"alternateName": "Lupus Coagulation Inhibitor",
"code": {
"@type": "MedicalCode",
"code": "D016682",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Schmitz",
"url": "https://questionsmedicales.fr/author/Thomas%20Schmitz",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany."
}
},
{
"@type": "Person",
"name": "Charlotte A Bäuml",
"url": "https://questionsmedicales.fr/author/Charlotte%20A%20B%C3%A4uml",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany."
}
},
{
"@type": "Person",
"name": "Diana Imhof",
"url": "https://questionsmedicales.fr/author/Diana%20Imhof",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address: dimhof@uni-bonn.de."
}
},
{
"@type": "Person",
"name": "Jeremy W Jacobs",
"url": "https://questionsmedicales.fr/author/Jeremy%20W%20Jacobs",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine, Yale School of Medicine, 330 Cedar Street, New Haven, CT, 06520, USA. Jeremy.jacobs@yale.edu."
}
},
{
"@type": "Person",
"name": "Jiraphorn Issara-Amphorn",
"url": "https://questionsmedicales.fr/author/Jiraphorn%20Issara-Amphorn",
"affiliation": {
"@type": "Organization",
"name": "Medical Microbiology, Interdisciplinary and International Program, Graduate School, Chulalongkorn University, Bangkok, Thailand."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Effect of Mean Platelet Volume to Platelet Count Ratio on Mortality in Peritoneal Dialysis.",
"datePublished": "2022-11-10",
"url": "https://questionsmedicales.fr/article/36405991",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/6922809"
}
},
{
"@type": "ScholarlyArticle",
"name": "Neonatal Thrombocytopenia: Factors Associated With the Platelet Count Increment Following Platelet Transfusion.",
"datePublished": "2023-08-11",
"url": "https://questionsmedicales.fr/article/37572863",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jpeds.2023.113666"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of platelet count and platelet transfusion on fever duration in patients with febrile neutropenia.",
"datePublished": "2022-07-20",
"url": "https://questionsmedicales.fr/article/35855637",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/08880018.2022.2066236"
}
},
{
"@type": "ScholarlyArticle",
"name": "Platelet count, temperature and pH value differentially affect hemostatic and immunomodulatory functions of platelets.",
"datePublished": "2023-01-27",
"url": "https://questionsmedicales.fr/article/36738664",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.thromres.2023.01.026"
}
},
{
"@type": "ScholarlyArticle",
"name": "Platelet count in preeclampsia: a systematic review and meta-analysis.",
"datePublished": "2023-04-24",
"url": "https://questionsmedicales.fr/article/37098392",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ajogmf.2023.100979"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"item": "https://questionsmedicales.fr/mesh/D019774"
},
{
"@type": "ListItem",
"position": 4,
"name": "Inhibiteur lupique de la coagulation",
"item": "https://questionsmedicales.fr/mesh/D016682"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteur lupique de la coagulation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteur lupique de la coagulation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteur lupique de la coagulation",
"description": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels sont les signes cliniques associés ?\nLe diagnostic nécessite-t-il des antécédents médicaux ?\nPeut-on avoir un inhibiteur sans lupus ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Platelet+Count#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteur lupique de la coagulation",
"description": "Quels sont les symptômes courants ?\nLes symptômes varient-ils d'une personne à l'autre ?\nY a-t-il des symptômes spécifiques aux femmes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?\nPeut-on avoir des symptômes sans saignement ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Platelet+Count#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteur lupique de la coagulation",
"description": "Peut-on prévenir l'inhibiteur lupique ?\nQuels conseils de mode de vie peuvent aider ?\nLes femmes enceintes doivent-elles être surveillées ?\nY a-t-il des vaccinations recommandées ?\nComment gérer le stress pour prévenir les symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Platelet+Count#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteur lupique de la coagulation",
"description": "Quels traitements sont disponibles ?\nLes anticoagulants sont-ils toujours nécessaires ?\nY a-t-il des effets secondaires aux traitements ?\nLe traitement est-il à vie ?\nLes traitements sont-ils efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Platelet+Count#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteur lupique de la coagulation",
"description": "Quelles sont les complications possibles ?\nLes complications sont-elles fréquentes ?\nComment prévenir les complications ?\nLes complications peuvent-elles être graves ?\nY a-t-il des signes d'alerte pour les complications ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Platelet+Count#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteur lupique de la coagulation",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe stress peut-il être un facteur de risque ?\nY a-t-il des facteurs environnementaux ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Platelet+Count#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests de coagulation et la détection d'anticorps spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de temps de céphaline activée (TCA) et les tests d'anticorps anti-cardiolipine sont courants."
}
},
{
"@type": "Question",
"name": "Quels sont les signes cliniques associés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des saignements anormaux et des thromboses, souvent sans cause apparente."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il des antécédents médicaux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de lupus ou d'autres maladies auto-immunes sont importants."
}
},
{
"@type": "Question",
"name": "Peut-on avoir un inhibiteur sans lupus ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est possible d'avoir un inhibiteur lupique sans diagnostic de lupus, bien que rare."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des saignements, des ecchymoses, et des douleurs thoraciques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la nature des symptômes peuvent varier considérablement entre les individus."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux femmes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent éprouver des symptômes liés à la grossesse, comme des complications thromboemboliques."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent s'aggraver, surtout sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans saignement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent présenter des symptômes thromboemboliques sans saignement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'inhibiteur lupique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Quels conseils de mode de vie peuvent aider ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles être surveillées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance étroite est nécessaire pour prévenir les complications pendant la grossesse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccinations recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations doivent être discutées avec un médecin, surtout pour les immunodéprimés."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pour prévenir les symptômes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de gestion du stress, comme la méditation, peuvent aider à réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des anticoagulants et des immunosuppresseurs pour gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les anticoagulants sont-ils toujours nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, leur nécessité dépend de la gravité des symptômes et des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent avoir des effets secondaires, comme des saignements ou des infections."
}
},
{
"@type": "Question",
"name": "Le traitement est-il à vie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la réponse au traitement et de l'évolution de la maladie, souvent à long terme."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des traitements sont efficaces pour contrôler les symptômes et prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des thromboses, des AVC et des problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent survenir, mais leur fréquence dépend de la gestion de la maladie."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement approprié et un suivi régulier peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être graves ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent être graves et nécessiter une intervention médicale urgente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'alerte pour les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques ou des troubles neurologiques doivent alerter immédiatement."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le sexe féminin, des antécédents familiaux et d'autres maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque est plus élevé chez les jeunes femmes, généralement entre 15 et 45 ans."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies auto-immunes augmentent le risque d'inhibiteur lupique."
}
},
{
"@type": "Question",
"name": "Le stress peut-il être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains médicaments ou à des agents environnementaux peut être un facteur."
}
}
]
}
]
}
Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address: dimhof@uni-bonn.de.
Publications dans "Inhibiteur lupique de la coagulation" :
Translational Research in Inflammation and Immunology Research Unit (TRIRU), Department of Microbiology, Chulalongkorn University, Bangkok, Thailand, aleelahavanit@gmail.com.
Publications dans "Inhibiteur lupique de la coagulation" :
Department of Pathology and Laboratory Medicine , University of North Carolina at Chapel Hill , 819 Brinkhous-Bullitt Building , Chapel Hill , North Carolina 27599 , United States.
Publications dans "Inhibiteur lupique de la coagulation" :
Mean platelet volume to platelet count ratio (MPV/PC) has been found to be an independent risk factor for mortality in various diseases, including cardiovascular disease, cancer, and hemodialysis. We ...
We conducted a retrospective cohort study at a single center and enrolled 1473 PD patients who were catheterized at our PD center from January 1, 2006, to December 31, 2013. All patients were divided ...
Our results indicated that low MPV/PC level was an independent risk factor for all-cause and CV mortality in PD patients aged less than 60 years....
To understand better those factors relevant to the increment of rise in platelet count following a platelet transfusion among thrombocytopenic neonates....
We reviewed all platelet transfusions over 6 years in our multi-neonatal intensive care unit system. For every platelet transfusion in 8 neonatal centers we recorded: (1) platelet count before and aft...
We evaluated 1797 platelet transfusions administered to 605 neonates (median one/recipient, mean 3, and range 1-52). The increment was not associated with gestational age at birth, postnatal age at tr...
The magnitude of post-transfusion rise was unaffected by most variables we studied. However, the increment was lower in neonates with consumptive thrombocytopenia, after pathogen reduction, with longe...
Platelets play a role in hemostasis, thrombosis, and vascular integrity. They also play a major role in the development of inflammation and the activation of immune responses. They have phagocytic act...
Platelets are primarily recognized for their role in hemostasis, but also regulate immune responses by interacting with leukocytes. Their highly sensitive nature enables platelets to rapidly respond t...
Many studies have reported the association between platelets and preeclampsia. However, sample sizes were small, and their findings were inconsistent. We conducted a systematic review and meta-analysi...
A systematic literature search was performed using Medline, Embase, ScienceDirect, Web of Science, Cochrane Library, NICHD-DASH, LILACS, and Scopus from inception to April 22, 2022....
Observational studies comparing platelet count between women with preeclampsia and normotensive pregnant women were included....
The mean differences with 95% confidence interval in platelet count were calculated. Heterogeneity was assessed using I...
A total of 56 studies comprising 4892 preeclamptic and 9947 normotensive pregnant women were included. Meta-analysis showed that platelet count was significantly lower in women with preeclampsia than ...
This meta-analysis confirmed that platelet count was significantly lower in preeclamptic women, irrespective of severity and presence or absence of associated complications, even before the onset of p...
Megakaryocytes (MKs), a kind of functional hematopoietic stem cell, form platelets to maintain platelet balance through cell differentiation and maturation. In recent years, the incidence of blood dis...
Platelet transfusion is commonly performed in infants to correct severe thrombocytopenia or prevent bleeding. Exploring the associations of platelet transfusion, platelet count (PC), and mean platelet...
To evaluate the associations of platelet transfusion, PC, and MPV with IVH and in-hospital mortality and to explore whether platelet transfusion-associated IVH and mortality risks vary with PC and MPV...
This retrospective cohort study included preterm infants who were transferred to the neonatal intensive care unit on their day of birth and received ventilation during their hospital stay. The study w...
Platelet transfusion, PC, and MPV....
Any grade IVH, severe IVH (grade 3 or 4), and in-hospital mortality....
Among the 1221 preterm infants (731 [59.9%] male; median [IQR] gestational age, 31.0 [29.0-33.0] weeks), 94 (7.7%) received 166 platelet transfusions. After adjustment for potential confounders, plate...
In preterm infants, platelet transfusion, PC, and MPV were associated with mortality, and PC was also associated with any grade IVH and severe IVH. The findings suggest that a lower platelet transfusi...
The familial chylomicronemia syndrome (FCS) is an ultra rare disease caused by lipoprotein lipase (LPL) deficiency associated with potentially lethal acute pancreatitis risk. Thrombocytopenia (platele...
To evaluate post-prandial fluctuations in the platelet count (PLC) and functional defects of hemostasis in FCS....
PLC, functional defects in hemostasis and hematologic variables were measured up-to 5 h after a meal in 6 homozygotes for FCS causing gene variants (HoLPL), 6 heterozygotes for LPL loss-of-function va...
Hourly post-prandial PLC was significantly lower in HoLPL than in controls (P < 0.009). Compared to the other groups, the PLC tended to decrease rapidly (in the first hour) post-meal in HoLPL (P = 0.0...
The PLC decreases post-prandially in FCS (HoLPL), is not associated with changes in functional defects of hemostasis and correlates with the NLR, a marker of acute pancreatitis severity....
This study aimed to evaluate the role of platelet count (PLT) in the prognosis of patients with acute respiratory distress syndrome (ARDS)....
The data were extracted from the Medical Information Mart for Intensive Care database (version 2.2). Patients diagnosed with ARDS according to criteria from Berlin Definition and had the platelet coun...
Overall, the final analysis included 3,207 eligible participants with ARDS. According to the Kaplan-Meier curves for 28-day mortality of PLT, PLT ≤ 100 × 10...
PLT appeared to be an independent predictor of mortality in critically ill patients with ARDS....
Linezolid (LZD) is one of the antibiotics used to treat methicillin-resistant Staphylococcus aureus. In Japan, the dose of LZD is not generally adjusted by renal function or therapeutic drug monitorin...
Fifty-five critically ill patients with existing thrombocytopenia (platelet count < 100 ×103 /μL) who received LZD for five days or more during the period from January 2011 to October 2018 were includ...
Mean (± standard error) platelet count prior to initiation of LZD was 47 ± 4 ×103 /uL, which increased significantly to 86 ± 13 ×103 /uL on day 15 (p<0.01). Median [interquartile range] duration of LZ...
Thrombocytopenia in critically ill patients in the ICU did not worsen after initiation of LZD therapy, and may be considered for the treatment of MRSA in this setting....
